Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa

1 Dec 2018

Abstract excerpt

BACKGROUND: Hydroxyurea is an effective treatment for sickle cell anemia, but few studies have been conducted in sub-Saharan Africa, where the burden is greatest. Coexisting conditions such as malnutrition and malaria may affect the feasibility, safety, and benefits of hydroxyurea in low-resource settings. METHODS: We enrolled children 1 to 10 years of age with sickle cell anemia in four sub-Saharan countries....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Hemoglobinopathies and Related Disorders
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30501550
DOI: 10.1056/nejmoa1813598

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan AfricaPMID 30501550Read ↗

Hydroxyurea for Children and Adults with Hemoglobin SC DiseaseSemantic proximity Read ↗

Hydroxyurea in the sickle cell disease modern eraSemantic proximity Read ↗

Epidemiology and treatment of relative anemia in children with sickle cell disease in sub-Saharan Africa.Semantic proximity Read ↗

Fixed Low-Dose Hydroxyurea Therapy: A Strategy for Reducing Emergency Room Visits and Improving Treatment Adherence in Paediatric Sickle Cell Anaemia in Resource-Limited SettingsSemantic proximity Read ↗

Optimizing hydroxyurea therapy for sickle cell anemia.Semantic proximity Read ↗

A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapySemantic proximity Read ↗

Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern UgandaSemantic proximity Read ↗

Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern UgandaSemantic proximity Read ↗

Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.Semantic proximity Read ↗

Economic Burden and Clinical Effectiveness of Different Hydroxyurea Dosing Regimens in Sickle Cell Disease: Evidence from NepalSemantic proximity Read ↗

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension studySemantic proximity Read ↗

Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.